Sources: Amgen mulling bid for Actelion

Rumors of a possible takeover of Switzerland's Actelion, a Roche spinout, turned red hot after the company merely noted that it is always engaged in routine talks with other biopharma companies. And Amgen fanned the flames when it declined to comment on rumors that it is angling to acquire the company. According to Bloomberg, Amgen is considering a bid for Actelion to gain drugs for rare diseases. Report

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.